TAVALISSE is the first agent that targets spleen tyrosine kinase (SYK), inhibiting downstream signaling IN cITP
Inhibiting downstream SYK signaling may help limit immune-mediated platelet destruction (SCROLL DOWN TO SEE THE STEPS)





*The active metabolite of TAVALISSE is R406.
TAVA_ITP-19165 1119